Rhabdomyolysis in Patients with Hemoblastoses during Intensive Chemotherapy
https://doi.org/10.15360/1813-9779-2009-4-60
Abstract
Objective: to define the clinical significance of rhabdomyolysis in patients with hemoblastoses during intensive chemotherapy. Subjects and methods. The study included 63 hematoblastosis patients aged 20 to 71 years (median 42 years) who received intensive chemotherapy that was referred as to grade 4 hematological toxicity. Serum myoglobin levels were monitored before and during chemotherapy, in the period of development of myelotoxic agranulocytosis and at the end of the treatment. Along with this, hematological shifts, biochemical parameters, and changes in acid-base and water-electrolytic balances were estimated. The condition was assessed using the APACHE II scale and organ dysfunctions were evaluated by the SOFA scale. The presence or absence of the systemic inflammatory response syndrome (SIRS) was determined. Results. The study revealed a 16-fold increase in myoglobin levels along with significant changes in laboratory indices. Myoglobinemia was found to be associated with the incidence of SIRS. The level of myoglobulin directly correlates with the severity of the disease, by using the APACHE II scale, and the degree of the SOFA scale organ dysfunctions. Multivariate analysis was used to define a role of the elevated level of myoglobin as an additional indicator of a poor prognosis. Conclusion. The findings suggest that muscular tissue damage is a manifestation of multiple organ dysfunctions and may be one of the key links of the development of a vicious circle of the pathogenesis of multiple organ failures. The obtained results necessitate the elaboration of measures to prevent or diminish muscular tissue damage in patients with hemoblastoses. Taking into account muscle damages can improve a prognosis when multiple organ failures develop. Key words: myoglobin, rhabdomyolysis, hemoblastoses, systemic inflammation, severity scales, prognosis.
References
1. Румянцев А. Г., Масчан А. А., Самочатова Е. В.
2. Волкова М. А.(ред.) Клиническая онкогематология. М.: Медицина; 2001.
3. Jackson S. R., Tweeddale M. G., Barnett M. J. et al.Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors. Bone Marrow Transplant. 1998; 21 (7): 697—704.
4. Evison J., Rickenbacher P., Ritz R. et al.Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. Swiss Med. Wkly 2001; 131 (47—48): 681—686.
5. Hinds C. J, Martin R., Quinton P.Intensive care for patiens with medical complications of haematological malignancy: is it worth it? Schweiz. Med. Wochenschr. 1998; 128 (39): 1467—1473.
6. Poletti V., Trisolini R., Tura S.Pulmonary disease in patients with hema-tologic malignancies. Sarcoidosis Vasc. Diffuse Lung Dis. 2002; 19 (1): 29—45.
7. Gabow P. A., Kaehny W. D., Kelleher S. P.The spectrum of rhabdomyol-ysis. Medicine; 1982.
8. Sauret J. M., Marinides G., Wang G. K.Rhabdomyolysis. Am. Fam. Physician. 2002; 65 (5): 907—912.
9. Заугольников В. С., Теплова Н. Н.Рабдомиолиз в клинической практике. Вятский мед. вестн. 2002; 3: 7—11.
10. Farmer Christopher J.Rhabdomyolysis In: Civetta M. (ed.) Critical Care. 3rd ed. Philadelphia (PA): Lippincott-Raven Publishers; 1997. 2195—2202.
11. Margolis D., Ross E., Miller K. B.Rhabdomyolysis associated with high-dose cytarabine. Cancer Treat. Rep. 1987; 71 (12): 1325—1326.
12. Truica C. I., Frankel S. R.Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am. J. Hematol. 2002; 70 (4): 320—323.
13. Blanco J. R., Zabalza M., Salcedo J. et al.Rhabdomyolysis of infectious and noninfectious causes. South Med. J. 2002; 95 (5): 542—544.
14. Larner A. J.Potassium depletion and rhabdomyolysis. BMJ 1994; 308 (6921): 136.
15. Shintani S., Shiigai T., Tsukagoshi H.Marked hypokalemic rhabdomyol-ysis with myoglobinuria due to diuretic treatment. Eur. Neurol. 1991; 31 (6): 396—398.
16. Rossi M. R., Longoni D. V., Rovelli A. M., Uderzo C.Severe rhabdomyol-ysis, hyperthermia and shock after amphotericin B colloidal dispersion in an allogeneic bone marrow transplant recipient. Pediatr. Infect. Dis. J. 2000; 19 (2): 172—173.
17. Ruiz-Contreras J., Rodriguez R., Gomez de Quero P. et al.Severe hypokalemia and rhabdomyolysis associated with itraconazole therapy. Pediatr. Infect. Dis. J. 2003; 22 (11): 1024—1025.
18. D’Agnillo F., Wood F., Porras C. et al.Effects of hypoxia and glutathione depletion on hemoglobin- and myoglobin-mediated oxidative stress toward endothelium. Biochim. Biophys. Acta 2000; 1495 (2): 150—159.
19. Iwata M., Zager R. A.Myoglobin inhibits proliferation of cultured human proximal tubular (HK-2) cells. Kidney Int. 1996; 50 (3): 796—804.
20. Reeder B. J., Sharpe M. A., Kay A. D. et al.Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and sub-arachnoid haemorrhage. Biochem. Soc. Trans. 2002; 30 (4): 745—748.
21. Чернов В. Н., Химичев В. Г., Бабиев В. Ф.Сывороточный МГ как показатель эндотоксикоза при острой непроходимости тонкой кишки. Хирургия 1999; 4: 43—46.
22. Титов В. Н., Кошкина Т. И., Волкова Е. И.Миоглобин крови: диагностическое значение и методы исследования. Клин. лаб. диагностика 1993; 3: 3—10.
23. Margolis D.Rhabdomyolysis associated with high-dose cytarabine. Cancer Treat. Rep. 1987; 71 (12): 1325—1326.
24. Truica C. I., Frankel S. R.Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am. J. Hematol. 2002; 70 (4): 320—323.
25. Переводчикова Н. И.(ред.) Химиотерапия опухолевых заболеваний. Краткое руководство. М.; 2000.
26. Miller A. B., Hoogstraten B., Staquet M., Winkler A.Reporting results of cancer treatment. Cancer 1981; 47 (1): 207—214.
27. Knochel J. P, Schlein E. M.On the mechanism of rhabdommyolisis in potassium depletion. J. Clin. Invest. 1972; 51 (7): 1750—1758.
28. Hund E.Myopathy in critically ill patients. Crit. Care Med. 1999; 27 (11): 2544—2547.
29. Motomura M.Critical illness polyneuropathy and myopathy. Rinsho Shinkeigaku. 2003; 43 (11): 802—804.
30. Burnham E. L., Moss M., Ziegler T. R.Myopathies in critical illness: characterization and nutritional aspects. J. Nutr. 2005; 135 (7): 1818—1823.
Review
For citations:
Lyanguzov A.V., Kolotilov L.V., Zagoskina T.P. Rhabdomyolysis in Patients with Hemoblastoses during Intensive Chemotherapy . General Reanimatology. 2009;5(4):60. (In Russ.) https://doi.org/10.15360/1813-9779-2009-4-60
Views:
1114
Email this article 